A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

* Males or females between 18 and 65 years, inclusive, at time of Screening * Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control * Subject has never received antiviral treatment for hepatitis C infection * Chronic HCV Genotype-1 infection prior to study enrollment

* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) * Females who are pregnant or plan to become pregnant, or breastfeeding * Any current or past clinical evidence of cirrhosis * Screening laboratory analyses that showing abnormal laboratory results * Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV * Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol * Positive screen for drugs or alcohol